ArticleEuropean radiology2025

RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab.

Dong Hwan Kim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.